FPRX Stock UPDATES Five Prime Therapeutics Inc (FPRX) 12.20 10/21/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Five Prime Therapeutics Inc (FPRX) 12.20 $FPRX

Five Prime Therapeutics Appoints Bill Ringo to Its Board of Directors
GlobeNewswire - Thu Oct 02, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced the appointment of Bill Ringo, a strategic advisor at Sofinnova Ventures, to the company's Board of Directors. The addition of Mr. Ringo increases the number of directors from eight to nine.
FPRX: 12.20 (+0.12)

Five Prime Therapeutics elects Dr. Robert Sikorski as VP of Global Clinical Development
M2 - Thu Sep 18, 5:41AM CDT
Biotechnology company Five Prime Therapeutics (FPRX) disclosed on Wednesday the election of Dr. Robert Sikorski, M.D., Ph.D., as vice president of its Global Clinical Development.
FPRX: 12.20 (+0.12)

Five Prime Therapeutics' Novel Target Licensed by Glaxo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 5:00PM CDT
Five Prime Therapeutics, Inc. (FPRX) will get $1.5 million with Glaxo exercising its option under their 2010 agreement.
CBM: 17.88 (+0.14), BMY: 51.95 (+1.39), GSK: 43.63 (+0.02), FPRX: 12.20 (+0.12)

Five Prime Therapeutics Appoints Dr. Robert Sikorski as Vice President of Global Clinical Development
GlobeNewswire - Wed Sep 17, 3:05PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced the appointment of Robert Sikorski, M.D., Ph.D., as Vice President of Global Clinical Development. Dr. Sikorski will oversee the global clinical development activities for Five Prime's product candidates.
FPRX: 12.20 (+0.12)

Five Prime Therapeutics Announces Option Exercise by GlaxoSmithKline for a Commercial License to a Novel Muscle Disease Target
GlobeNewswire - Mon Sep 15, 3:39PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, announced today that GlaxoSmithKline (GSK) has exercised its option to obtain an exclusive, worldwide license to products containing or directed to an undisclosed muscle disease target that Five Prime discovered using its proprietary library of human extracellular proteins and target screening and discovery capabilities.
GSK: 43.63 (+0.02), FPRX: 12.20 (+0.12)

Five Prime Therapeutics to Present at Morgan Stanley 2014 Global Healthcare Conference
GlobeNewswire - Wed Sep 03, 12:29PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime, will present at the Morgan Stanley 2014 Global Healthcare Conference on Tuesday, September 9 at 5:15 PM Eastern Time. The conference will take place at the Grand Hyatt in New York City.
FPRX: 12.20 (+0.12), MS: 34.06 (+0.74)

How Five Prime Therapeutics (FPRX) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 7:33AM CDT
Five Prime Therapeutics (FPRX) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. It currently has a Zacks Industry Rank of 72 out of more than 250 industries.
FPRX: 12.20 (+0.12)

Five Prime Therapeutics (FPRX) Jumps: Stock Adds 10.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 7:51AM CDT
Five Prime Therapeutics, Inc. (FPRX) was a big mover last session, as its shares rose over 10% on the day.
CBM: 17.88 (+0.14), GILD: 106.67 (+4.46), FPRX: 12.20 (+0.12)

Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
CLSN: 2.63 (+0.03), NWBO: 5.09 (+0.25), CVM: 0.69 (-0.16), CLDX: 14.74 (-0.41), INCY: 52.44 (+1.65), AZN: 69.00 (+1.05), MRK: 55.13 (+1.08), DNDN: 1.10 (-0.03), NLNK: 34.50 (+3.06), PPHM: 1.48 (-0.02), BMY: 51.95 (+1.39), FPRX: 12.20 (+0.12)

Five Prime Therapeutics Announces Second Quarter 2014 Financial Results
GlobeNewswire - Tue Aug 05, 3:09PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the second quarter that ended June 30, 2014.
FPRX: 12.20 (+0.12)

Five Prime Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 5, 2014
GlobeNewswire - Tue Jul 29, 3:12PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its second quarter 2014 financial results on Tuesday, August 5, 2014, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Tuesday, August 5, 2014 at 5:00 p.m. (ET)/2:00 p.m. (PT) to discuss the company's financial results and provide a general business update.
FPRX: 12.20 (+0.12)

Why Is Wall Street Gobbling Up These 2 Small-Cap Biotech Stocks?
George Budwell, The Motley Fool - Motley Fool - Tue Jul 08, 9:55AM CDT
When institutional investors start buying large blocks of shares in a company, it could be a good sign that the stock is getting positive attention because of its potential to move higher. In the last quarter, we saw institutions dramatically...
BMY: 51.95 (+1.39), PRTA: 19.81 (-0.33), FPRX: 12.20 (+0.12)

Five Prime Therapeutics to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 01, 5:52PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Aron Knickerbocker, Chief Business Officer, will present at the 13 Annual Needham Healthcare Conference on April 8, 2014 at 4:20 PM Eastern Time. The conference will take place at the Westin Grand Central Hotel in New York City.
FPRX: 12.20 (+0.12)

Five Prime Therapeutics Announces Upcoming Presentations at the 2014 American Association for Cancer Research Meeting
GlobeNewswire - Thu Mar 27, 6:28PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that data related to FP-1039 (GSK3052230), an FGF ligand trap in a global, multi-arm Phase 1b study, and FPA144, a monoclonal antibody against the FGF receptor 2b, will be presented at the American Association for Cancer Research (AACR) Annual Meeting. The meeting will be held April 5-9, 2014 in San Diego, CA.
FPRX: 12.20 (+0.12)

Big Pharma's Not-So-Hidden Secret to Success
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 27, 11:05AM CDT
The past week may have been a bit of a bumpy ride for the pharmaceutical and biotech sector following congressional testimony that highlighted the rising cost of branded drugs, but it represents nothing more than a tiny hurdle in what's been an...
PFE: 28.28 (+0.35), THRX: 18.64 (+0.69), GSK: 43.63 (+0.02), BMY: 51.95 (+1.39), FPRX: 12.20 (+0.12)

Bristol Myers Deal Overshadows Q4 loss at Five Prime - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 10:00AM CDT
Amidst the excitement about the Bristol-Myers deal, Five Prime reported its fourth quarter 2013 results.
ALXN: 174.48 (+6.28), BMY: 51.95 (+1.39), FPRX: 12.20 (+0.12)

Biotech Stock Roundup: GILD Letter Triggers Major Selloff - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 9:13AM CDT
Are the good days over for the biotech sector or is this just a correction?
MDVN: 96.97 (+1.99), AGEN: 3.00 (+0.02), BIIB: 326.77 (+15.36), ECYT: 5.58 (-0.03), CBST: 66.40 (-0.94), GILD: 106.67 (+4.46), GERN: 2.16 (-0.02), ICPT: 225.71 (-5.62), BMY: 51.95 (+1.39), MNKD: 5.53 (+0.17), FPRX: 12.20 (+0.12)

Five Prime Therapeutics posts higher net loss of USD28.9m in fiscal 2013
M2 - Wed Mar 26, 6:02AM CDT
US-based biotechnology company Five Prime Therapeutics (NasdaqGS:FPRX) stated on Tuesday net loss of USD28.9m (USD5.23 per basic and diluted share) for the year ended 31 December 2013.
FPRX: 12.20 (+0.12)

Five Prime Therapeutics Announces Fourth Quarter and Fiscal 2013 Financial Results
GlobeNewswire - Tue Mar 25, 3:30PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended Dec. 31, 2013.
BMY: 51.95 (+1.39), FPRX: 12.20 (+0.12)

This Week in Biotech: Endocyte Doubles, Intercept Wobbles, and Geron Gets Smacked Again
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 22, 12:45PM CDT
With the  SPDR S&P Biotech Index  up  57% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
AGEN: 3.00 (+0.02), SNTA: 3.06 (-0.07), ECYT: 5.58 (-0.03), GERN: 2.16 (-0.02), ICPT: 225.71 (-5.62), AMGN: 144.09 (+6.58), FPRX: 12.20 (+0.12)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 7

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 0

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Ericsson Completes Major Buyback in November Burst

Updated Category News Views 65

Ericsson's Aggressive Share Repurchase Strategy Ericsson's share buyback spree might not be the first rodeo for seasoned investors out there, but their recent grab between November 9th and 13th surely made a few heads turn. The telecom giant snatched up a neat pile of 500,000 of its own Class B shares, maintaining the steady tick of their ambitious buyback program. It's...

Continue Reading
LONGWELL's New Axial Fan Selection Guide Unveiled

Updated Category News Views 75

LONGWELL's New Fan Brochure Shakes Up Data Center Cooling Alright, let's cut to the chase. LONGWELL, the folks out in Ningbo who live and breathe HVACR and industrial fans, have dropped a new tool that’s going to have OEM engineers raising a glass. This twelve-page axial fan selection guide is a stroke of genius—or at least that's what those of us who've braved the...

Continue Reading
Ozelle Unveils AI-Powered Hematology Tool at MEDICA 2026

Updated Category News Views 116

Pioneering a New Era in Hematology In the fast-paced world of blood analysis, standing still means being left in the dust. Ozelle, with its AI-powered innovative tool, is making waves at MEDICA 2026 in Düsseldorf. Meet O-Cyte 1, an automated hematology analyzer that's merging high-resolution cell imaging with routine CBC (Complete Blood Count) testing. Sounds like...

Continue Reading
Fluence Energy Faces Heat: Class Action Lawsuit Unfolds

Updated Category News Views 25

Fluence Energy's Difficult Waters Investors in Fluence Energy (NASDAQ: FLNC) are having a moment of reckoning, no doubt. November 2nd saw a nearly 9% drop in FLNC stock, further fueled by the sudden departures of the CEO and CFO just days earlier. This marks a bitter chapter for Fluence as its stock continues to bleed, leaving many wondering what seismic shifts are yet to...

Continue Reading
Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 50

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
SwitchBot's Hub 4: A Step Toward a Connected Future

Updated Category News Views 37

Turning a House Into a Smart Home Haven Out of Tokyo and onto the world stage, SwitchBot's got something new cooking that might just shake up the smart home scene. They've launched the Hub 4, a gadget that's like the Swiss Army knife of home control. For those who like things simple, this is a one-hub-to-rule-them-all kind of deal. 101,000 Reasons to Notice Now, they...

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 33

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 11

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Smart Waste Management Market Growth Insights

Updated Category News Views 124

Overview of the Smart Waste Management Market In recent years, the smart waste management market has garnered substantial attention, projected to transition from $2.2 billion in valuation to an impressive $8.3 billion. This surge reflects a remarkable compound annual growth rate (CAGR) of 15.6% from 2024 to 2032. The driving force behind this growth stems from increasing...

Continue Reading
Exploring the Collaborative Spirit at the China-US Event

Updated Category News Views 150

Celebrating Cultural Connections The recent 'My China Album' event highlighted the importance of cultural exchanges between the United States and China, focusing on the shared journeys and experiences of citizens from both nations. Strengthening Relations through Understanding During this special occasion, the ambassador emphasized the collaborative spirit that can propel...

Continue Reading
Exciting New Active Adult Community Launches in Central Oregon

Updated Category News Views 143

Welcoming Active Adults to Dry Canyon Introducing Dry Canyon, an extraordinary gated community designed specifically for those aged 55 and better. This remarkable development offers active adults a perfect blend of resort-style living and scenic beauty, all nestled in the heart of Central Oregon. As part of this celebration, Lennar, a well-respected name among...

Continue Reading
XTI Aerospace Announces Upcoming Town Hall for Stakeholders

Updated Category News Views 153

XTI Aerospace Invites Stakeholders to Upcoming Town Hall Updates on Tri-Fan 600, Valkyrie AI and Vanguard Platform ENGLEWOOD, Colo. – XTI Aerospace, Inc. (NASDAQ: XTIA) is at the forefront of advancing vertical flight technologies. The company is making exciting progress with its next-generation vertical takeoff and landing (VTOL) aircraft, the TriFan 600. XTI Aerospace...

Continue Reading
Big Lots Launches Discounts and Donations for Vets in November

Updated Category News Views 47

Big Lots Supports Veterans and Active Military with November Campaigns Every November, Big Lots makes a concerted effort to give back to veterans and active military members. This initiative is a part of their commitment to recognizing the sacrifices made by those who serve our country. Highlighting their respect for military service, Big Lots introduces various discounts...

Continue Reading